Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $33.8 million.

  • Inhibrx Biosciences' Operating Expenses fell 2774.75% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.4 million, marking a year-over-year decrease of 5816.63%. This contributed to the annual value of $331.6 million for FY2024, which is 5005.27% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Operating Expenses is $33.8 million, which was down 2774.75% from $28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Operating Expenses registered a high of $161.0 million during Q2 2024, and its lowest value of $28.7 million during Q2 2025.
  • For the 3-year period, Inhibrx Biosciences' Operating Expenses averaged around $61.4 million, with its median value being $46.4 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 28917.55% in 2024, then tumbled by 8218.05% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Operating Expenses (Quarter) stood at $89.9 million in 2023, then plummeted by 44.37% to $50.0 million in 2024, then crashed by 32.41% to $33.8 million in 2025.
  • Its Operating Expenses was $33.8 million in Q3 2025, compared to $28.7 million in Q2 2025 and $42.9 million in Q1 2025.